Advertisement
NTRA vs SMTI
Which Stock Would AI Choose? Natera, Inc. (NTRA) vs. Sanara MedTech Inc. (SMTI) Stock Comparison
Key Takeaways
- NTRA exhibits stronger revenue growth, with recent quarters showing increases over 30%, compared to SMTI's approximately 5% rise in its latest reported quarter.
- NTRA's market capitalization stands at around $29.6 billion, dwarfing SMTI's $181 million, highlighting differences in scale and liquidity.
- Both stocks have delivered solid one-year returns near 37-39%, with SMTI edging out year-to-date at 15.5% versus NTRA's 9.5%.
- Analyst coverage is optimistic for both, with average price targets implying significant upside potential relative to current levels.
- NTRA benefits from catalysts in oncology and prenatal testing, while SMTI focuses on wound care and surgical solutions.
- Recent market activity shows NTRA gaining from positive analyst initiations and partnerships, amid broader biotech momentum.
Introduction
This stock comparison examines NTRA and SMTI, two healthcare innovators navigating distinct niches within medical technology and diagnostics. Investors and traders analyzing relative performance in the biotech and medtech sectors may find value here, particularly those seeking exposure to growth-oriented small- to mid-cap names. With both stocks demonstrating resilience amid market volatility, this analysis highlights key metrics, recent developments, and positioning to inform portfolio decisions or trading strategies focused on sector-specific opportunities and stock comparison dynamics.
NTRA Overview and Recent Performance
NTRA, or Natera, Inc., specializes in cell-free DNA testing for oncology, women's health, and organ health. Its portfolio includes Signatera for cancer monitoring (MRD, or minimal residual disease) and Panorama for non-invasive prenatal testing. Trading around $207, the stock's 52-week range spans $132 to $256, reflecting volatility typical of growth biotechs.
In recent market activity, NTRA has shown upward momentum, supported by robust revenue growth—Q4 2025 revenues hit $665.5 million, up over 39% year-over-year. Full-year results underscored sustained expansion in product adoption. Positive sentiment stems from analyst initiations like William Blair's Outperform rating, partnerships enhancing AI models, and upcoming Q1 2026 earnings. These factors have bolstered investor confidence, driving shares higher despite broader sector pressures.
SMTI Overview and Recent Performance
SMTI, Sanara MedTech Inc., develops surgical and wound care solutions, including CellerateRX collagen products, BIASURGE irrigation solutions, and bone grafts like BiFORM. Priced near $20, its 52-week range is $16 to $36, indicative of small-cap fluctuations.
Recent quarters reflect steady progress, with Q4 2025 net revenue at $27.5 million, a 5% increase, pushing full-year totals past $103 million for the first time. While earnings slightly missed estimates, revenue met expectations, and full-year 2026 guidance was reaffirmed. Market sentiment has been influenced by new analyst coverage, such as Lake Street's Buy rating with a $32 target. Shares have benefited from product expansions in post-acute care, though small-cap risks temper gains in recent trading sessions.
Trending AI Robots
Tickeron's Trending AI Robots page curates the top 25 performers from over 350 AI trading bots that analyze thousands of tickers across diverse strategies, timeframes, and styles—from short-term scalping to longer-term trend following. These bots deliver real-time signals for copy trading, boasting impressive stats: annualized returns ranging from 68% to 163%, win rates of 51% to 88%, profit factors up to 7.12, and profit-to-drawdown ratios exceeding 17 in top cases. Whether focusing on semiconductors, small caps, or volatility plays, only the most suitable for current conditions earn a spot. Explore these high-performing bots to enhance your trading edge.
Head-to-Head Comparison
NTRA and SMTI operate in complementary healthcare segments: diagnostics-driven molecular testing for NTRA versus device-based wound and bone solutions for SMTI. Growth drivers differ markedly—NTRA's high-single-digit revenue acceleration contrasts SMTI's lower-teens potential amid niche expansions.
Recent momentum is comparable one-year, but NTRA offers superior liquidity and analyst backing. Risk factors include biotech regulatory hurdles for NTRA and execution risks in sales for smaller SMTI. Sector exposure ties both to healthcare tailwinds like aging populations, yet NTRA aligns more with precision medicine trends, while SMTI leverages surgical demand. Market sentiment favors NTRA's scale in relative performance metrics.
Tickeron AI Verdict
Tickeron's AI models currently lean toward NTRA due to its trend consistency, explosive revenue growth, and positioning amid positive catalysts like partnerships and earnings anticipation. While SMTI shows promise in steady execution, NTRA's larger scale and momentum suggest higher probability of outperformance in the near term, based on observable market data.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTRA is a Hold and SMTI is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NTRA’s FA Score shows that 0 FA rating(s) are green whileSMTI’s FA Score has 1 green FA rating(s).
- NTRA’s FA Score: 0 green, 5 red.
- SMTI’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NTRA’s TA Score shows that 3 TA indicator(s) are bullish while SMTI’s TA Score has 7 bullish TA indicator(s).
- NTRA’s TA Score: 3 bullish, 6 bearish.
- SMTI’s TA Score: 7 bullish, 3 bearish.
Price Growth
NTRA (@Medical Specialties) experienced а -4.00% price change this week, while SMTI (@Pharmaceuticals: Other) price change was +11.11% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +9.54%. For the same industry, the average monthly price growth was +2.29%, and the average quarterly price growth was -4.23%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.56%. For the same industry, the average monthly price growth was -3.93%, and the average quarterly price growth was +47.01%.
Reported Earning Dates
NTRA is expected to report earnings on Jul 30, 2026.
SMTI is expected to report earnings on Aug 17, 2026.
Industries' Descriptions
@Medical Specialties (+9.54% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Pharmaceuticals: Other (-0.56% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| NTRA | SMTI | NTRA / SMTI | |
| Capitalization | 28.1B | 208M | 13,510% |
| EBITDA | -227.7M | 4.78M | -4,768% |
| Gain YTD | -14.427 | -2.741 | 526% |
| P/E Ratio | N/A | 378.50 | - |
| Revenue | 2.5B | 102M | 2,452% |
| Total Cash | 1.09B | 14.9M | 7,302% |
| Total Debt | 240M | 47.4M | 506% |
NTRA | SMTI | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 18 | 16 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 56 Fair valued | 95 Overvalued | |
PROFIT vs RISK RATING 1..100 | 51 | 100 | |
SMR RATING 1..100 | 94 | 99 | |
PRICE GROWTH RATING 1..100 | 60 | 50 | |
P/E GROWTH RATING 1..100 | 100 | 2 | |
SEASONALITY SCORE 1..100 | n/a | 15 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NTRA's Valuation (56) in the Biotechnology industry is somewhat better than the same rating for SMTI (95) in the null industry. This means that NTRA’s stock grew somewhat faster than SMTI’s over the last 12 months.
NTRA's Profit vs Risk Rating (51) in the Biotechnology industry is somewhat better than the same rating for SMTI (100) in the null industry. This means that NTRA’s stock grew somewhat faster than SMTI’s over the last 12 months.
NTRA's SMR Rating (94) in the Biotechnology industry is in the same range as SMTI (99) in the null industry. This means that NTRA’s stock grew similarly to SMTI’s over the last 12 months.
SMTI's Price Growth Rating (50) in the null industry is in the same range as NTRA (60) in the Biotechnology industry. This means that SMTI’s stock grew similarly to NTRA’s over the last 12 months.
SMTI's P/E Growth Rating (2) in the null industry is significantly better than the same rating for NTRA (100) in the Biotechnology industry. This means that SMTI’s stock grew significantly faster than NTRA’s over the last 12 months.
| NTRA | SMTI | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 89% |
| Stochastic ODDS (%) | 1 day ago 84% | 1 day ago 83% |
| Momentum ODDS (%) | 1 day ago 82% | 1 day ago 72% |
| MACD ODDS (%) | 1 day ago 75% | 1 day ago 73% |
| TrendWeek ODDS (%) | 1 day ago 77% | 1 day ago 77% |
| TrendMonth ODDS (%) | 1 day ago 80% | 1 day ago 73% |
| Advances ODDS (%) | 1 day ago 80% | 1 day ago 77% |
| Declines ODDS (%) | 22 days ago 78% | 10 days ago 79% |
| BollingerBands ODDS (%) | 1 day ago 76% | 1 day ago 84% |
| Aroon ODDS (%) | 1 day ago 82% | 1 day ago 72% |
Advertisement